Imperial College London: Global Trial Reports on Use of Tocilizumab in COVID-19 Pneumonia
March 30, 2021
March 30, 2021
LONDON, England, March 30 (TNSJou) -- Imperial College London issued the following news:
The anti-inflammatory treatment tocilizumab does not significantly improve outcomes for patients with severe COVID-19 pneumonia, a trial has found.
However, researchers found that tocilizumab reduced the time the patients spent in hospital by an average of 8.4 days and reduced time spent in the ICU by an average of 6 days.
The COVACTA randomised controlled trial was the . . .
The anti-inflammatory treatment tocilizumab does not significantly improve outcomes for patients with severe COVID-19 pneumonia, a trial has found.
However, researchers found that tocilizumab reduced the time the patients spent in hospital by an average of 8.4 days and reduced time spent in the ICU by an average of 6 days.
The COVACTA randomised controlled trial was the . . .